Does “Asymptomatic” Mean Without Symptoms for Those Living with HIV Infection? by Willard, Suzanne et al.
eCommons@AKU
School of Nursing & Midwifery, East Africa Faculty of Health Sciences, East Africa
July 2009
Does “Asymptomatic” Mean Without Symptoms
for Those Living with HIV Infection?
Suzanne Willard
Elizabeth Glaser Pediatric AIDS Foundation
William L. Holzemer
UCSF School of Nursing
Dean J. Wantland
UCSF School of Nursing
Yvette P. Cuca
UCSF School of Nursing
Kenn M. Kirksey
SETON Family of Hospitals
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/eastafrica_fhs_sonam
Part of the Nursing Midwifery Commons
Recommended Citation
Willard, S., Holzemer, W. L., Wantland, D. J., Cuca, Y. P., Kirksey, K. M., Portillo, C. J., Corless, I. B., Rivero-Méndez, M., Rosa, M. E.,
Nicholas, P. K., Hamilton, M., Sefcik, E., Kemppainen, J., Canaval, G., Robinson, L., Moezzi, S., Human, S., Arudo, J., Eller, L. S.,
Bunch, E., Dole, P. J., Coleman, C., Nokes, K., Reynolds, N. R., Tsai, Y., Maryland, M., Voss, J., Lindgren, T. (2009). Does
“Asymptomatic” Mean Without Symptoms for Those Living with HIV Infection?. AIDS Care - Psychological and Socio-Medical Aspects
of AIDS/HIV, 21(3), 322-328.
Available at: http://ecommons.aku.edu/eastafrica_fhs_sonam/2
Authors
Suzanne Willard, William L. Holzemer, Dean J. Wantland, Yvette P. Cuca, Kenn M. Kirksey, Carmen J.
Portillo, Inge B. Corless, Marta Rivero-Méndez, María E. Rosa, Patrice K. Nicholas, Mary Jane Hamilton,
Elizabeth Sefcik, Jeanne Kemppainen, Gladys Canaval, Linda Robinson, Shahnaz Moezzi, Sarie Human, John
Arudo, Lucille Sanzero Eller, Eli Bunch, Pamela J. Dole, Christopher Coleman, Kathleen Nokes, Nancy R.
Reynolds, Yun-Fang Tsai, Mary Maryland, Joachim Voss, and Teri Lindgren
This article is available at eCommons@AKU: http://ecommons.aku.edu/eastafrica_fhs_sonam/2
Does “Asymptomatic” Mean Without Symptoms for Those
Living with HIV Infection?
Suzanne Willard, PhD, CRNP, FAAN,
Assistant Professor, Drexel University, College of Nursing and Health Professions, Elizabeth
Glaser Pediatric AIDS Foundation, 1140 Connecticut Avenue, NW, Suite 200, Washington, DC
20036, T: 202 448-8491
William L. Holzemer, RN, PhD, FAAN,
Professor and Associate Dean, UCSF School of Nursing, 2 Koret Way, Box 0608, San Francisco,
CA 94143-0608, T: 415-476-2763, F: 415-476-6042
Dean J. Wantland, RN, PhD,
Assistant Adjunct Professor, UCSF School of Nursing, 2 Koret Way, Box 0608, San Francisco,
CA 94143-0608, T: 415-613-4107, F: 415-476-6042
Yvette P. Cuca, MPH, MIA,
Project Director, UCSF School of Nursing, 2 Koret Way, Box 0608, San Francisco, CA
94143-0608, T: 415-502-8081, F: 415-476-6042
Kenn M. Kirksey, RN, PhD,
Director of Nursing Research, SETON Family of Hospitals, 1601 Rio Grande, Suite 300, Austin,
Texas 78701, T: 512-324-8988
Corresponding Author: William L. Holzemer, RN, PhD, FAAN, Professor and Associate Dean, UCSF School of Nursing, 2 Koret
Way, Box 0608, San Francisco, CA 94143-0608, T: 415-476-2763, F: 415-476-6042, bill.holzemer@nursing.ucsf.edu.
Author contributions
Willard: Study design, data collection, data analysis, manuscript writing
Holzemer: Study design, data collection, data analysis, manuscript writing
Wantland: Study design, data collection, data analysis, manuscript writing
Cuca: Data collection, manuscript writing
Kirksey: Study design, data collection, data analysis
Portillo: Study design, data collection, data analysis
Corless: Study design, data collection, manuscript review
Rivero: Study design, data collection
Rosa: Study design, data collection
Nicholas: Study design, data collection oversight; manuscript review
Hamilton: Study design, data collection
Sefcik: Study design, data collection
Kemppainen: Study design, data collection, manuscript writing
Canaval: Study design, data collection, data analysis
Robinson: Study design, data collection
Moezzi: Study design, data collection
Human: Study design, data collection
Arudo: Study design, data collection
Sanzero Eller: Study design, data collection
Bunch: Study design, data collection
Dole: Study design, data collection
Coleman: Study design, data collection
Nokes: Study design, data collection
Reynolds: Study design, data collection
Tsai: Study design, data collection
Maryland: Data collection
Voss: Study design, data analysis, manuscript review
Lindgren: Study design, data collection
NIH Public Access
Author Manuscript
AIDS Care. Author manuscript; available in PMC 2013 April 19.
Published in final edited form as:
AIDS Care. 2009 March ; 21(3): 322–328. doi:10.1080/09540120802183511.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Carmen J. Portillo, RN, PhD,
Professor, UCSF School of Nursing, 2 Koret Way, Box 0608, San Francisco, CA 94143-0608, T:
415-476-1630, F: 415-476-6042
Inge B. Corless, RN, PhD, FAAN [Professor],
MGH Institute of Health Professions, CNY 36 1st Ave, Boston, MA 02129, T: 617-726-8018, F:
617-724-6321
Marta Rivero-Méndez, RN, DNS,
Professor, University of Puerto Rico, Medical Sciences Campus, School of Nursing, P.O. Box
365067, San Juan, Puerto Rico 00936-5067, T: 787-758-2525, x2114, F: 787-281-0721
María E. Rosa, DrPH, PhD, CARN,
Dean and Professor, Universidad del Turabo, School of Health Sciences, PO Box 3030, Gurabo,
PR 00778, T: 787-743-7979 x 4017/4462, F: 787-704-2703
Patrice K. Nicholas, DNSc, MPH, RN, ANP,
Director of Global Health and Academic Partnerships, Professor, MGH Institute of Health
Professions, Brigham and Women’s Hospital, One Brigham Circle 4th Floor, Boston, MA 02115,
T: 617-525-7790
Mary Jane Hamilton, RN, PhD,
Dean & Professor, Texas A&M University - Corpus Christi, College of Nursing & Health Science,
6300 Ocean Drive, Corpus Christi, TX 78412, T: 361-825-2649, F: 361-825-2484
Elizabeth Sefcik, PhD, RNCS,
Professor, Texas A&M University - Corpus Christi, 6300 Ocean Drive, Corpus Christi, TX 78412,
T: 361-825-5857
Jeanne Kemppainen, RN, PhD,
Associate Professor, School of Nursing, The University of North Carolina at Wilmington, 1080 St.
Joseph St., 3B, Carolina Beach, NC 28428, T: 910-962-3202, H: 910-458-3788
Gladys Canaval, RN, MSc, PhD,
Universidad del Valle, A.A. 25360 Cali, Valle, Colombia, T: 57-2-3391437 ext 110, F:
57-2-5581938
Linda Robinson, PhD, ACRN,
Associate Professor, University of San Diego, Hahn School of Nursing, 5998 Alcala Park, San
Diego, CA, T: 619-260-4571, F: 619-260-6814
Shahnaz Moezzi, PhD, RN,
Assistant Professor, University of Utah, College of Nursing, 1340 Michigan Ave., Salt Lake City,
UT 84105, T: 801-587-9128, F: 801-581-4642
Sarie Human, D Cur,
University of South Africa, Department of Health Studies, PO Box 392, Unisarand, UNISA,
Pretoria, 0003, South Africa, T: 27-12-429-6290, F: 27-12-429-6688
John Arudo, BSN, MPH, MSc,
Regional Research Co-ordinator, Aga Khan University Advanced Nursing Programme, PO Box
39340-00623, Nairobi, Kenya, T: 254-20-374-74-83, F: 254-20-374-7004
Lucille Sanzero Eller, PhD, RN,
Associate Professor, Rutgers, the State University of New Jersey, 180 University Ave., Suite 102,
Newark, NJ 07102, T: 973-353-5326 x503, F: 973-353-1277
Eli Bunch, DNSc, RN,
Professor, University of Oslo, Institute of Nursing Science, POB 1153, Blindern, 0318, Oslo
Norway, T: 47-22-85-05-60, F: 47-22-85-05-70
Willard et al. Page 2
AIDS Care. Author manuscript; available in PMC 2013 April 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pamela J. Dole, EdD, MPH, FNP, ACRN,
Village Diagnostic and Treatment Center, 121A W 20th Street, New York, NY 10011, T:
212-337-9290, F: 212-337-9254
Christopher Coleman, PhD, MPH, APRN-BC, ACRN,
University of Pennsylvania, School of Nursing, Philadelphia, PA 19104-6096, T: 215-898-0760, F:
215-573-7496
Kathleen Nokes, PhD, RN, FAAN,
Professor, Hunter College, CUNY, Hunter-Bellevue School of Nursing, 425 East 25th St., Box
874, New York, NY 10010, T: 212-481-7594, F: 212-481-4427
Nancy R. Reynolds, RN, PhD, FAAN,
Yale University, School of Nursing, P.O. Box 9740, 100 Church Street South, Suite 200, New
Haven, CT 06536-0740, T: 203-737-2313, F: 203-785-6455
Yun-Fang Tsai, RN, PhD,
Professor, School of Nursing, Chang Gung University, 259 Wen Hua 1st Road, Kwei-Shan, Tao-
Yuan 333, Taiwan, ROC, T: 011-886-3-3283016 ext 5958, F: 011-886-3-211868
Mary Maryland, PhD, APRN-BC,
University of Illinois at Chicago, College of Medicine, Hematology Oncology, 820 S. Wood St.,
Suite 172 (M/C 712), Chicago, Illinois 60612, T: 312-413-2042, F: 312-996-5984
Joachim Voss, PhD, RN, and
Assistant Professor, University of Washington, School of Nursing, Dept. of Biobehavioral Nursing
and Health Systems, UW Box 357266, Room T 624B, Seattle, WA 98195, T: 206-616-7819, F:
206-543-4771
Teri Lindgren, RN, MS, MPH, PhD
Project Director, UCSF School of Nursing, 2 Koret Way, Box 0606, San Francisco, CA
94143-0606, T: 415-504-7892
Suzanne Willard: swillard@pedaids.org; William L. Holzemer: bill.holzemer@nursing.ucsf.edu; Dean J. Wantland:
dean.wantland@ucsf.edu; Yvette P. Cuca: yvette.cuca@nursing.ucsf.edu; Kenn M. Kirksey: kmkirksey@seton.org;
Carmen J. Portillo: carmen.portillo@nursing.ucsf.edu; Inge B. Corless: icorless@mghihp.edu; Marta Rivero-Méndez:
mrivero@rcm.upr.edu; María E. Rosa: mrosa@suagm.edu; Patrice K. Nicholas: pnicholas@mghihp.edu; Mary Jane
Hamilton: mary.hamilton@tamucc.edu; Elizabeth Sefcik: esefcik@falcon.tamucc.edu; Jeanne Kemppainen:
kemppainenj@uncw.edu; Gladys Canaval: glacanav@univalle.edu.co; Linda Robinson: lindar@sandiego.edu; Shahnaz
Moezzi: shahnaz.moezzi@nurs.utah.edu; Sarie Human: humansp@unisa.ac.za; John Arudo: jarudo@aku.ac.ke; Lucille
Sanzero Eller: eller@rutgers.edu; Eli Bunch: e.h.bunch@medisin.uio.no; Pamela J. Dole: pamjean@aol.com; Christopher
Coleman: colemanc@nursing.upenn.edu; Kathleen Nokes: kathy.nokes@aol.com; Nancy R. Reynolds:
nancy.reynolds@yale.edu; Yun-Fang Tsai: yftsai@mail.cgu.edu.tw; Mary Maryland: mmaryland94@aol.com; Joachim
Voss: vossj@u.washington.edu; Teri Lindgren: teri.lindgren@nursing.ucsf.edu
Abstract
Throughout the history of the HIV epidemic, HIV-positive patients with relatively high CD4
counts and no clinical features of opportunistic infections have been classified as “asymptomatic”
by definition and treatment guidelines. This classification, however, does not take into
consideration the array of symptoms that an HIV-positive person can experience long before
progressing to AIDS. This short report describes two international multi-site studies conducted in
2003–2005 and 2005–2007. Results from the studies show that HIV-positive people may
experience symptoms throughout the trajectory of their disease, regardless of CD4 count or
classification. Providers should discuss symptoms and symptom management with their clients at
all stages of the disease.
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BACKGROUND
In untreated HIV disease, more than ten years can elapse from initial infection to the first
occurrence of an opportunistic infection (OI), an indicator that the disease has progressed to
AIDS (Panel on Antiretroviral Guidelines for Adult and Adolescents, 2006). This period of
time does not mean, however, that people infected with HIV who have not yet progressed to
AIDS are symptom free. Existing definitions and care guidelines that categorize patients as
“asymptomatic” may lead clinicians to ignore symptoms that are not directly related to
opportunistic infections, but that do require attention.
In 1986, the Centers for Disease Control (CDC) (“Classification system for human T-
lymphotropic virus type III/lymphadenopathy-associated virus infections,” 1986) provided
an early description of HIV disease, which included two main categories: symptomatic and
asymptomatic. For two decades, these definitions have been incorporated into treatment
guidelines that have informed clinicians in the United States and other countries in their care
for patients.
In the mid-1990s, with the ability to treat HIV itself, many clinicians began focusing solely
on CD4 counts and symptoms directly related to OI (e.g. diarrhea, night sweats, fever).
There has been growing evidence, however, that HIV-positive people experience many
symptoms that are not directly related to OI or CD4 counts, particularly fatigue, depression,
muscle aches, and fear/worries (Corless, Nicholas, Davis, Dolan, & McGibbon, 2002;
Corless et al., In Press; Eller et al., 2005; Kemppainen et al., 2006; J. Voss, Portillo,
Holzemer, & Dodd, 2007; J. G. Voss, 2005). These symptoms often go unrecognized and
untreated by health care providers (Hughes, 2004), either because care providers do not ask
patients about their symptoms or because they consider the symptoms to be “sub-clinical”.
Siegel and colleagues (1999) reported that having symptoms, as well as their intensity,
influenced decisions to seek care and have contributed to reduced adherence to medications,
thereby increasing the likelihood of resistance to medication regimens and exacerbating
symptoms. These factors may also reduce the physical and mental aspects of a person’s
quality of life (Abel & Painter, 2003; Ammassari et al., 2001; Corless et al., 2002; Hudson,
Kirksey, & Holzemer, 2004; Lorenz, Cunningham, Spritzer, & Hays, 2006).
The aim of this study is to determine whether there are differences in the frequency and
intensity of self-reported HIV symptoms among three levels of CD4 count (<200 cells/mm3,
200–350 cells/mm3, >350 cells/mm3), regardless of use of ARVs.
METHODS
This study is a secondary analysis of two studies conducted under the auspices of the UCSF
International Nursing Network for HIV/AIDS Research (www.ucsf.edu/aidsnursing) (Table
1). The first study, “Self-Care Symptom Management in HIV/AIDS” (Study A) (Reynolds
et al., 2007) was a descriptive cross-sectional study examining self-reported symptoms and
self-care behaviors in 1,217 HIV-infected men and women from Colombia, Norway, Puerto
Rico, Taiwan and the United States. The second study, “The Efficacy of the HIV/AIDS
Symptom Management Manual” (Study B) (Wantland et al., in press), was a three-month,
repeated measures randomized controlled trial of 775 participants in Kenya, Puerto Rico,
South Africa, and the United States. Only the baseline data are used in this analysis.
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INSTRUMENTS
A Demographic Survey booklet was used to collect information on personal and
environmental characteristics (eg. age, gender, whether participants had adequate income).
Data on biological/physiological factors (eg. whether participants had received an AIDS
diagnosis, had comorbidities) were also collected.
The Revised Sign and Symptom Checklist for Persons with HIV Disease (SSC-HIVrev)
(Holzemer, Hudson, Kirksey, Hamilton, & Bakken, 2001) was used to capture the frequency
and intensity of 72 common HIV signs and symptoms experienced by the participant on the
day the checklist is completed. Items were rated on a 3-point Likert scale of 1 (mild), 2
(moderate), or 3 (severe). Reliability and validity of the instrument have been previously
reported for a U.S. sample (Holzemer et al., 2001). A Chinese version has been tested with a
Taiwanese sample (Tsai, Hsiung, & Holzemer, 2003). Slightly different Spanish versions
were used in Texas, Puerto Rico, and Colombia. In Africa, the English version was used.
Researchers at each site confirmed the content validity of the versions.
DATA ANALYSIS
Responses to the questionnaires were entered into Statistical Package for the Social Sciences
(SPSS) for Windows Version 13.0 software (SPSS, 2005). Descriptive statistics (i.e., means,
standard deviations, frequencies, and percents) were used to examine demographic
characteristics of the samples and the frequency and intensity of the symptoms. For the
purposes of this analysis, gynecological signs and symptoms were excluded. The
individuals’ self-reported CD4 values were stratified into three groups: 0–200, 201–350 and
>350 CD4 cells/mm3. In Study A, 26.8% of reporting participants had CD4 counts of 0–200
cells/mm3; 19.5% had counts of 201–350 cells/mm3; and 53.7% had counts greater than 350
cells/mm3. In Study B, 24.7% had CD4 counts of 0–200 cells/mm3; 21.1% had counts of
201–350 cells/mm3; and 54.1% had counts greater than 350 cells/mm3. Analysis of
covariance (ANCOVA) compared the mean number and intensity of symptoms reported by
the three groups, controlling for taking ARV medications at the time of the survey.
FINDINGS
Symptom Rankings
In both studies, the most frequently reported symptoms included both physical and
psychosocial symptoms: fatigue, depression, and muscle aches. Table 2 shows the ranking
of the twenty most frequently reported symptoms for both studies, with a frequency range of
33% to 60%.
Symptoms by CD4 Category
For Study A, the mean self-reported CD4 count was 433 (SD=413) and the average
symptom frequency was 18.3 (SD=16.8) (Table 3). The mean number of symptoms by CD4
category was: 0–200 cells/mm3 = 19.9 (SD=17.5); 201–350 cells/mm3 = 17.5 (SD=15.6);
and >350 cells/mm3 = 17.9 (SD=16.9). Of those reporting (n=820), 21.3% (n=175) were not
taking ARV medications. No differences were noted as to whether or not the participant was
taking ARV medications and the frequency or intensity of symptoms reported. ANCOVA
revealed a nonsignificant main effect of CD4 category on the frequency of reported
symptoms (F(2,820)=2.43, p = 0.12). There were no differences in the number of symptoms
among the three levels of CD4 counts. There was a significant lower report of symptom
intensity for those presently taking ARVs compared to those not taking ARVs
(F(1,718)=7.42, p=0.007), however similar to symptom frequency, there was no significant
difference between the CD4 categories in either ARV group (F(2,718)=0.44, p=0.64).
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For Study B, the mean self-reported CD4 count was 407 (SD=268) and the average
symptom frequency was 20.9 (SD=18.3). The mean number of symptoms by CD4 category
was: 0–200 cells/mm3 = 21.0 (SD=17.7); 201–350 cells/mm3 = 21.7 (SD=20.3); and >350
cells/mm3 = 20.4 (SD=17.8). Of those reporting, (n=477), 27.6% (n=132) were not taking
ARV medications. Again, there was no effect on whether or not the participant was taking
ARV medications and the frequency of symptoms reported. ANCOVA revealed a
nonsignificant main effect of CD4 category on the frequency of reported symptoms
(F(2,479)=0.20, p = 0.82). There were no differences in the number of symptoms among the
three levels of CD4 counts. The interaction between taking/not taking ARV medications and
CD4 category was not significant with similar results (F(2,479)=0.46, p=0.63). In Study B,
there was also no significant difference in the report of symptom intensity for those
presently taking ARVs compared to those not taking ARVs and, similar to Study A, there
was no significant difference between the CD4 categories in either ARV group
(F(2,448)=0.47, p=0.62). Results from both studies show that the symptom frequency and
intensity for those taking ARV medications and those not taking ARVs were similar by CD4
category (Table 3). Intensity of symptoms in both studies demonstrates a wide SD. This
indicates a broad variation in how patients perceive and rate their symptom experience.
DISCUSSION
The data from these studies demonstrate that the term “asymptomatic” HIV disease is not a
valid term, as patients do experience symptoms regardless of their CD4 count or lack of OIs.
The data also reveal that self-reported symptoms are present in individuals regardless of
whether they are taking ARVs. Clearly, there are symptoms associated with all levels of
CD4 classification.
Based on developments in HIV treatment and care, and the findings reported here, the
authors recommend that clinicians no longer use the term “asymptomatic” to define their
HIV-positive clients’ treatment needs. Clinicians should carefully interview patients as to
the presence of symptoms regardless of CD4 count and should address symptom
management. The wide variability of symptoms’ intensity lends credence to further
interview of the patients to explore their illness experience and seek methods to improve
quality of life. The danger of labeling someone living with HIV infection as “asymptomatic”
is the failure to recognize the constellation of symptoms they are experiencing, on or off
ARVs, across the spectrum of CD4 counts. Clinical practice guidelines have been shown to
be an effective means of improving the way clinicians manage patients, and it is important
for HIV clinical practice guidelines to reflect the fact that HIV-positive people may
experience symptoms throughout their disease, and that these must be managed to improve
quality of life.
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Table 2
Twenty Most Frequently Reported Symptoms (percentage of participants reporting each symptom)
Symptom Study A (N=1,217) Study B (N=775)
Frequency % n Frequency % n
Fatigue 60 630 57 446
Depression 58 706 56 432
Muscle aches 56 681 55 425
Weakness 53 643 53 408
Thirst 52 635 52 389
Worry 50 605 50 388
Difficulty concentrating 50 610 51 392
Memory loss 49 591 49 376
Dry mouth 48 583 50 387
Insomnia 45 551 48 371
Joint pain 44 578 50 386
Diarrhea 41 501 38 291
Shortness of breath with activity 41 503 42 326
Night sweats 39 473 39 299
Gas/bloating 39 475 41 314
Headaches 37 446 41 319
Abdominal pain 36 434 38 297
Numbness/tingling of hands/fingers 34 408 39 303
Numbness/tingling of feet/toes 33 400 44 339
Numbness/tingling of legs 33 403 37 286
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